Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia

Cancer

Volumn 122, Issue 2, 2016, Pages 304-311

  Churpek, Jane E ^a   Marquez, Rafael ^a   Neistadt, Barbara ^a   Claussen, Kimberly ^a   Lee, Ming K ^b   Churpek, Matthew M ^a   Huo, Dezheng ^a   Weiner, Howard ^a   Bannerjee, Mekhala ^a   Godley, Lucy A ^a   Le Beau, Michelle M ^a   Pritchard, Colin C ^c   Walsh, Tom ^b   King, Mary Claire ^b   Olopade, Olufunmilayo I ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

breast cancer; inherited; leukemia; therapy related

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA; DOXORUBICIN; GROWTH FACTOR; MEMBRANE PROTEIN; MYELOID GROWTH FACTOR; PARTNER AND LOCALIZER OF BRCA2 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; BREAST CANCER; BREAST CARCINOGENESIS; CANCER REGISTRY; CANCER RISK; CANCER SURVIVOR; CANCER SUSCEPTIBILITY; CHROMOSOME ABERRATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; THERAPY RELATED ACUTE LYMPHOBLASTIC LEUKEMIA; THERAPY RELATED LEUKEMIA; THERAPY RELATED MYELOID NEOPLASM; UNITED STATES; AGE; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVOR; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LEUKEMIA, RADIATION-INDUCED; MIDDLE AGED; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVORS;

EID: 84954075396     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29615     Document Type: Article

References (33)

1. Abdulwahab A, Sykes J, Kamel-Reid S, Chang H, Brandwein JM,. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012; 118: 3962-3967.
2. Kayser S, Dohner K, Krauter J, et al., The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011; 117: 2137-2145.
3. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M,. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia-a review of 101 cases. Ann Oncol. 2008; 19: 1634-1638.
4. Smith SM, Le Beau MM, Huo D, et al., Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102: 43-52.
5. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
6. Godley LA, Larson RA,. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35: 418-429.
7. Le Deley MC, Suzan F, Cutuli B, et al., Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007; 25: 292-300.
8. Smith RE, Bryant J, DeCillis A, Anderson S,; National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003; 21: 1195-1204.
9. Wolff AC, Blackford AL, Visvanathan K, et al., Risk of marrow neoplasms after adjuvant breast cancer therapy: the National Comprehensive Cancer Network experience. J Clin Oncol. 2015; 33: 340-348.
10. Morton LM, Dores GM, Tucker MA, et al., Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013; 121: 2996-3004.
11. Shaffer LG, McGowan-Jordan J, Schmid M, eds. ISCN: An International System for Human Cytogenetic Nomenclature. 1st ed. Basel, Switzerland: S. Karger; 2013.
12. Walsh T, Lee MK, Casadei S, et al., Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010; 107: 12629-12633.
13. Nord AS, Lee M, King MC, Walsh T,. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics. 2011; 12: 184.
14. Pritchard CC, Salipante SJ, Koehler K, et al., Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2014; 16: 56-67.
15. Dohner H, Estey EH, Amadori S, et al,; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474.
16. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ,. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat. 2009; 118: 593-598.
17. Schulz E, Valentin A, Ulz P, et al., Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet. 2012; 49: 422-428.
18. Martin MG, Jacoby M, Shao J, Deych E, Graubert T, Walter MJ,. BRCA1 and BRCA2 nucleotide variants in young women with therapy-related acute myeloid leukemia [abstract]. Blood. Nov 2009; 114: 1102. Abstract 1102.
19. D'Andrea AD,. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010; 362: 1909-1919.
20. Rosenberg PS, Alter BP, Ebell W,. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica. 2008; 93: 511-517.
21. Scardocci A, Guidi F, D'Alo F, et al., Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer. 2006; 95: 1108-1113.
22. Risch HA, McLaughlin JR, Cole DE, et al., Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68: 700-710.
23. Birch JM, Alston RD, McNally RJ, et al., Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20: 4621-4628.
24. Gonzalez KD, Noltner KA, Buzin CH, et al., Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27: 1250-1256.
25. Patel JP, Gonen M, Figueroa ME, et al., Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089.
26. Ben-Yehuda D, Krichevsky S, Caspi O, et al., Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood. 1996; 88: 4296-4303.
27. Shih AH, Chung SS, Dolezal EK, et al., Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013; 98: 908-912.
28. Thompson D, Seal S, Schutte M, et al., A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2542-2545.
29. Hall MJ, Li L, Wiernik PH, Olopade OI,. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006; 47: 765-767.
30. Chandra P, Luthra R, Zuo Z, et al., Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol. 2010; 133: 686-693.
31. Lalloo F, Varley J, Ellis D, et al., Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet. 2003; 361: 1101-1102.
32. John EM, Miron A, Gong G, et al., Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007; 298: 2869-2876.
33. Malone KE, Daling JR, Doody DR, et al., Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006; 66: 8297-8308.